Bolt Biotherapeutics, Inc. Operating Cash Flow
Bolt Biotherapeutics, Inc. (BOLT) reported Operating Cash Flow of -$14.56 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- Bolt Biotherapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$6.54M.
- Bolt Biotherapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$8.02M.
- Bolt Biotherapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$7.16M.
- Bolt Biotherapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$9.73M.
- Bolt Biotherapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$39.85M.
- Bolt Biotherapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$61.29M.
- Bolt Biotherapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$69.53M.
- Bolt Biotherapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$76.50M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$6.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$14.56M 10-Q · filed 2026-08-11 | -$21.72M derived: sum of 3 quarters · filed 2026-08-11 | -$31.45M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$8.02M 10-Q · filed 2026-05-12 | -$15.18M derived: sum of 2 quarters · filed 2026-05-12 | -$24.91M derived: sum of 3 quarters · filed 2026-05-12 | -$34.51M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$7.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$16.89M derived: sum of 2 quarters · filed 2026-03-12 | -$26.48M derived: sum of 3 quarters · filed 2026-08-11 | -$39.85M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$9.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$19.33M derived: sum of 2 quarters · filed 2026-08-11 | -$32.69M 10-Q · filed 2025-11-12 | -$47.12M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$9.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$22.96M 10-Q · filed 2026-08-11 | -$37.39M derived: sum of 3 quarters · filed 2026-08-11 | -$51.36M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$13.37M 10-Q · filed 2026-05-12 | -$27.80M derived: sum of 2 quarters · filed 2026-05-12 | -$41.76M derived: sum of 3 quarters · filed 2026-05-12 | -$57.90M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$14.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$28.40M derived: sum of 2 quarters · filed 2026-03-12 | -$44.54M derived: sum of 3 quarters · filed 2026-03-12 | -$61.29M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$13.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$30.11M derived: sum of 2 quarters · filed 2025-11-12 | -$46.86M 10-Q · filed 2025-11-12 | -$61.12M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$16.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$32.89M 10-Q · filed 2025-08-14 | -$47.16M derived: sum of 3 quarters · filed 2025-08-14 | -$63.91M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$16.75M 10-Q · filed 2025-05-12 | -$31.02M derived: sum of 2 quarters · filed 2025-05-12 | -$47.77M derived: sum of 3 quarters · filed 2025-05-12 | -$62.88M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$14.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$31.01M derived: sum of 2 quarters · filed 2025-03-24 | -$46.13M derived: sum of 3 quarters · filed 2025-03-24 | -$69.53M 10-K · filed 2025-03-24 |
| 2023-09-30 | -$16.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$31.86M derived: sum of 2 quarters · filed 2024-11-12 | -$55.26M 10-Q · filed 2024-11-12 | -$73.21M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$15.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$38.51M 10-Q · filed 2024-08-13 | -$56.46M derived: sum of 3 quarters · filed 2024-08-13 | -$69.91M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$23.40M 10-Q · filed 2024-05-14 | -$41.35M derived: sum of 2 quarters · filed 2024-05-14 | -$54.80M derived: sum of 3 quarters · filed 2024-05-14 | -$75.59M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$17.95M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$31.40M derived: sum of 2 quarters · filed 2024-03-21 | -$52.19M derived: sum of 3 quarters · filed 2024-03-21 | -$76.50M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$13.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$34.24M derived: sum of 2 quarters · filed 2023-11-09 | -$58.55M 10-Q · filed 2023-11-09 | -$76.35M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$20.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$45.10M 10-Q · filed 2023-08-07 | -$62.90M derived: sum of 3 quarters · filed 2023-08-07 | -$81.62M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | -$24.31M 10-Q · filed 2023-05-11 | -$42.11M derived: sum of 2 quarters · filed 2023-05-11 | -$60.84M derived: sum of 3 quarters · filed 2023-05-11 | -$64.82M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$17.79M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$36.52M derived: sum of 2 quarters · filed 2023-03-29 | -$40.51M derived: sum of 3 quarters · filed 2023-03-29 | -$57.07M 10-K · filed 2023-03-29 |
| 2021-09-30 | -$18.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$22.71M derived: sum of 2 quarters · filed 2022-11-10 | -$39.27M 10-Q · filed 2022-11-10 | -$52.16M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$3.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$20.55M 10-Q · filed 2022-08-10 | -$33.44M derived: sum of 3 quarters · filed 2022-08-10 | -$45.95M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$16.56M 10-Q · filed 2022-05-12 | -$29.45M derived: sum of 2 quarters · filed 2022-05-12 | -$41.96M derived: sum of 3 quarters · filed 2022-05-12 | -$54.23M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$12.89M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$25.41M derived: sum of 2 quarters · filed 2022-03-30 | -$37.67M derived: sum of 3 quarters · filed 2022-03-30 | -$47.31M 10-K · filed 2022-03-30 |
| 2020-09-30 | -$12.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$24.78M derived: sum of 2 quarters · filed 2021-11-09 | -$34.42M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$12.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$21.90M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$9.64M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |